-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 A5nIajjdZ86wGb21hxQrFGrFaWfI5c68qtlwuTOkUb8z3OEe9hQmyg4AZYIfnMVH
 Ki+pyDNFxS3UbwNyFT5gdg==

<SEC-DOCUMENT>0000950123-09-003993.txt : 20090506
<SEC-HEADER>0000950123-09-003993.hdr.sgml : 20090506
<ACCEPTANCE-DATETIME>20090304153022
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-09-003993
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="y01248cy0124805.gif" alt="(Morrison Foerster Letterhead)" width="80%">
</DIV>

<DIV align="center" style="margin-top: 18pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Writer&#146;s Direct Contact
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">212.468.8163</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">JTanenbaum@mofo.com</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt">March&nbsp;4, 2009
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Todd E. Hardiman<BR>
Associate Chief Accountant<BR>
Division of Corporation Finance<BR>
United States Securities and Exchange Commission<BR>
100 F. Street, N.E.<BR>
Washington, D.C. 20549
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">RE:</TD>
    <TD>&nbsp;</TD>
    <TD>Protalix BioTherapeutics, Inc.<BR>
Annual Report on Form&nbsp;10-K, filed March&nbsp;17, 2008<BR>
for the Fiscal Year Ended December&nbsp;31, 2007<BR>
File No.&nbsp;001-33357</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On behalf of our client, Protalix BioTherapeutics, Inc., a Florida corporation (the
&#147;Company&#148;), transmitted herewith are responses to the Staff&#146;s comments to the Company&#146;s Annual
Report on Form 10-K for the fiscal year ended December&nbsp;31, 2007 (the &#147;2007 Form 10-K&#148;). The
comments were delivered by the Staff to the Company and its counsel by way of telephone calls on
February&nbsp;18, 2009 and March&nbsp;3, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For ease of reference, we have noted the Staff&#146;s comments in bold faced type and the responses
in regular type.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please refer to your response to Comment 4. It is still not clear what the remaining 2,325,250
options represent. Please confirm whether any of these are employee options and please tell us the
accounting treatment relating to the issuance of those remaining options and subsequent vesting.
You state in Note 5(f) on page F-23 and in Note 5(g) on page F-27 of your 10-K that only 2,201,972
options were granted to employees during 2006.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>RESPONSE: </B>All of the remaining 2,325,250 options represent options that were issued to
nonemployees on December&nbsp;31, 2006. In accordance with Statement of Financial Accounting Standards
No.&nbsp;123 (revised 2004), &#147;Share-Based Payment,&#148; the Company recorded a portion of the expense for
the first vesting period of the options during the first three quarters of 2007. All
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the options expired in accordance with the terms of the options in the fourth quarter of 2007,
prior to the first vesting date of the options. Accordingly, the compensation expense of such
options were reversed for purposes of the fourth quarter of 2007, with no expense for the fiscal
year of 2007. The 2,201,972 options discussed in Note 5(f) on page F-23 and in Note 5(g) on page
F-27 of the 2007 Form 10-K for the year ended December&nbsp;31, 2007 are options that were granted to
employees in 2006 and are not related to the 2,325,250 options or the 387,542 options included in
Exhibit&nbsp;B of our response dated October&nbsp;16, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please revise your valuation methodology for the first and third quarters of 2007 with respect
to compensation expense of certain option grants to use the trading value of the stock or tell us
why no revision is necessary.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>RESPONSE: </B>In response to the Staff&#146;s comments and after consulting with the Audit Committee of the
Company&#146;s Board of Directors, the Company has determined that it should amend and restate its
financial statements for the year ended December&nbsp;31, 2007, and each of the fiscal quarters of 2007.
The Company intends to use the trading price of the Company&#146;s common stock on each quarter end in
preparing the restated financial statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In certain draft language reflecting the proposed restatement provided to the Staff by the
Company, the Company stated that it had previously issued 2,605,514 shares of equity instruments to
nonemployees whose terms indicated that performance was not complete until the applicable vesting
requirements were fulfilled. The Company subsequently provided the Staff with revised language
that stated that the number of such equity instruments issued to nonemployees was 2,148,569. The
Staff asked that the Company reconcile the two different numbers.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>RESPONSE: </B>The Company hereby clarifies that the correct number of equity instruments issued to
nonemployees during the first three quarters of 2007, whose terms indicated that performance was
not complete until the applicable vesting requirements were fulfilled, was 2,148,569 and that the
2,605,514 number was a typographical error. The Company refers the Staff to Exhibit&nbsp;B of its
October&nbsp;16, 2008 response. Exhibit&nbsp;B presents, in tabular form, an exhaustive list of all
non-employee issuances/grants by the Company based on a vesting date during 2007 and 2008. There
are three sets of issuances included in Exhibit&nbsp;B: (i)&nbsp;the grant of 1,753,027 options to a related
party; (ii)&nbsp;the grant of 387,542 options to a nonemployee; and (iii)&nbsp;the grant of 8,000 shares of
restricted common stock to a nonemployee. The three grants represent 2,148,569 shares of common
stock, in the aggregate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Staff requested that the Company explain how it remeasured recorded compensation expenses
with respect to certain options granted to nonemployees for the different quarters of 2007.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>RESPONSE: </B>To illustrate the Company&#146;s remeasurement calculations, the Company presents the options
to purchase 387,542 shares of common stock issued to a nonemployee on December&nbsp;31, 2006 (see
Exhibit&nbsp;B of the Company&#146;s October&nbsp;16, 2008 response). None of the shares underlying the options
vested during 2007. The first vesting date of the options was March&nbsp;1, 2008, which was 14&nbsp;months
after the date of grant. On that date, 40% of the shares underlying the options vested. For
individual tranches of options for which the applicable vesting/service
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">period crossed interim periods (such as the options issued to the nonemployee), the Company
remeasures the tranches at the end of each period until the final vesting date of the tranche. The
calculation of the proportionate compensation expense is as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To calculate the compensation expense for the options at the end of the first quarter of
2007, the Company divided three by 14; the number of months in the quarter over the number of
months in the vesting period and multiplied the result by 40%, the portion of the option that was
to vest during the vesting period. For purposes of determining the fair value of the options, the
Company&#146;s management used the closing sale price of the Common Stock on the NYSE Alternext US
(then, the American Stock Exchange) on March&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;To calculate the compensation expense for the options at the end of the second quarter of
2007, the Company divided six by 14; the cumulative number of months in the first two quarters of
2007 over the number of months in the vesting period and multiplied the result by 40%, the portion
of the option that was to vesting during the vesting period. For purposes of the second quarter,
the Company based the valuation on the closing sale price of the Company&#146;s Common Stock on the last
day of the quarter. Since the calculation for the second quarter included an adjustment for the
first quarter vesting, the compensation expense for the option for the first quarter of 2007, as
measured on March&nbsp;31, 2007, was remeasured using the reported traded price on June&nbsp;30, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;To calculate the compensation expense for the options at the end of the third quarter of
2007, the Company divided nine by 14; the cumulative number of months in the three quarters of 2007
over the number of months in the vesting period and multiplied the result by 40%, the portion of
the option that was to vest during the vesting period. The fair value of the options was based on
the closing sale price of the Company&#146;s Common Stock on September&nbsp;30, 2007. As a result, the
compensation expenses recorded for the first six months of 2007 with respect to the option, as
measured on June&nbsp;30, 2007, were remeasured using the closing sale price as of September&nbsp;30, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;&nbsp;To calculate the compensation expense for the option at the end of 2007, the Company
divided 12 by 14; the cumulative number of months in the four quarters of 2007 over the number of
months in the vesting period and multiplied the result by 40%, the portion of the option that was
to vest during the vesting period. The fair value of the options was based on the closing sale
price of the Company&#146;s Common Stock on December&nbsp;31, 2007. As a result, the compensation expenses
recorded for the first nine months of 2007 with respect to the options, as measured on September
30, 2007, were remeasured using the closing sale price as of December&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company notes that in the Quarterly Reports on Form 10-Q filed for the second and third quarter
of 2007, the Company did not remeasure the compensation expenses in connection with options held by
nonemployees in the manner discussed above. Rather, the Company continued to amortize the expense
for each quarter individually based on the fair value of the Company&#146;s Common Stock at the end of
the second and third quarter. Since the Company is restating its financial statements for such
quarters and although the effect of the remeasurements are immaterial, the Company has elected to
perform such remeasurements in the amended Quarterly Reports on Form 10-Q it intends to file in
connection with the restatement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Staff requested that the Company explain management&#146;s decision that effective internal
controls were in place as of the end of the 2007 fiscal year in light of the need to restate the
Company&#146;s financial statements.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Auditing Standard No.&nbsp;5, Section&nbsp;69, provides a list of potential indicators of a material weakness
in a company&#146;s internal control over financial reporting. One of the listed criteria is the
restatement of previously issued financial statements to reflect the correction of a material
misstatement. While assessing the effect of the restatement on the Company&#146;s internal control over
financial reporting and in light of Section&nbsp;69, the Company&#146;s management considered the following
factors:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The misstatement was not a result of a miscalculation of financial figures;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The misstatement is not a result of a typographical error;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Management reviewed and discussed the accounting treatment thoroughly and in-depth with
the Company&#146;s audit committee and Board of Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Management&#146;s decision not to use the closing sale price to calculate the fair value of
certain stock-based compensation issued to nonemployees was understood by all
aforementioned parties to be non-standard accounting treatment but all such parties agreed
that an alternative valuation mechanism was appropriate given the limited market for the
Company&#146;s Common Stock at that time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company disclosed its decision not to rely on the reported traded price to calculate
the fair value of certain stock-based compensation issued to nonemployees in each relevant
filing with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In light of the foregoing, the Company believes that the need to restate the financial statements
is the result of a difference in professional judgment. It was not caused by a failure of
management&#146;s internal control over financial reporting and procedures in connection with the
preparation of its financial statements. In addition, the need to restate the financial statements
was not the result of any design control deficiency or the lack of the operation of any controls
that were designed to operate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Management believes that it has adequate and effective internal controls relating to the
completeness and accuracy of stock-based compensation in place. These controls are designed to
apply the applicable rules, test for compliance, fraud and other factors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Management believes that its internal controls that relate to the recording of share-based
compensation for nonemployees were effective. The restatement results from the application of
professional judgment that the Company made regarding the application of the share based
compensation expense. Notwithstanding the need to change certain accounting treatment, the
Company&#146;s internal decision making process regarding accounting guidance was thorough, and included
all relevant controls including discussions with all relevant functionaries within the Company
relating to the financial reporting process. These functionaries include the Company&#146;s management,
consultants, audit committee and the board of directors. The Company elected to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">restate its financial statements and change the accounting treatment of its share-based payments
following the same internal control and accounting process. Since the Company believes that the
restatement was not the result of a failure of any internal control, the Company concluded that it did not need to disclose any changes in its internal
controls or financial reporting and concluded that it did not have a material weakness in its
internal controls as a result of the restatement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The
Company confirms that its independent registered public accounting
firm has completed its review of the amended Quarterly Reports on
Form&nbsp;10-Q/A.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please call the undersigned at the telephone number set forth above or Joseph Magnas at
212-336-4170 with any question or comment you may have regarding the responses set forth herein.
In addition, please send all written correspondence directly to the undersigned and Joseph Magnas
of Morrison &#038; Foerster LLP, 1290 Avenue of the Americas, New York, New York 10104, telecopy
212-468-7900, with copies to David Aviezer, Ph.D., the Company&#146;s President and Chief Executive
Officer, at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel, telecopy
&#043;972-4-988-9489.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">Sincerely,<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" style="border-bottom: 0px solid #000000" align="left">/s/ James R. Tanenbaum&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-top: 24pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">cc:</TD>
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.<BR>
Yossi Maimon</TD>
</TR>
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y01248cy0124805.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y01248cy0124805.gif
M1TE&.#EA\`.Q`/<``````(````"``("`````@(``@`"`@,'!P<#<P*;*\```
M``H*"A`0$!D9&1\?'RDI*3$Q,3DY.4)"0DI*2E)24EI:6F%A86IJ:G-S<WM[
M>X6%A8R,C)24E)R<G*:FIJZNKK6UM;R\O,;&QL[.SM?7U][>WN?GY^_O[_?W
M]_[^_@``````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````/_[\*&AH7]_?_\```#_
M`/__````__\`_P#______R'Y!```````+`````#P`[$`AP```(````"``("`
M````@(``@`"`@,'!P<#<P*;*\`````H*"A`0$!D9&1\?'RDI*3$Q,3DY.4)"
M0DI*2E)24EI:6F%A86IJ:G-S<WM[>X6%A8R,C)24E)R<G*:FIJZNKK6UM;R\
MO,;&QL[.SM?7U][>WN?GY^_O[_?W]_[^_@``````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````/_[\*&AH7]_?_\```#_`/__````__\`_P#______PC^`%,('$BP
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M")AW`SYHH&BGJ4=?@NA9!I]MPCEH'GHKUC?B9R;:QR&+,S*TDWX<]7=?=P&6
M:.*.'<:GFG_FW4@A9>6EMEZ%(1ZIX9-01BGE32BZ"-Z5!-)XHI/LB=CBAQ"^
M^&*35H)FH)$@;JE>C0B>^9&1:/[GVX'IN0DDF+`A2.1_M)$Y9I\V3DCGE(06
M:NBA'55Y99"*8AFF6W^!Q^:)SM4I7J4L+I<<<8(NV5YPD7*Z:*`?5J@3B=Z-
M.MZ/=>[)69S^1VI6:JN.PFIIC#"2FJFCB/;JZZ_`?IG9@*E"2N:>`G:I)IXI
M*INDF),^-UMDC(ZHXK)^19IG1G!B>:V'X%JYX&BR4MLFN25^JFZ+"N)I[J.\
M!BOOO/1:R&J68+KZKK/>EHEMHTD6:VF\T=+*([C%?NOOL_$V?)MVR`T67504
M5ZQ<Q#P!RBQ6LFJ+<5VU=16R<1+O!M9IFYI<;KTLM^PR4CB^)W"_0@YL[:CI
M#G>NJ6,*ZK#!87[+Y(Y?%GGNRT@GK?323+.DK[)^$EQKP"3WS"[#_!XMK-5`
MFRLTU4:+*6?839=M]MEHIVWFV%-+O2NOR19(MIU8/[TVM#?ORN'^UUYF5>2P
ML^:YLMJ$%V[XX5+"A5>YC(<E'9]L\79KRI%GJ]O@DD=<\ENA.LZQ62%S+O+$
ME2KN>7\>(Z[ZZJRW[OKKL,<N^^RTUV[[[;CGKOONO/?N^^_`!R_\\,07;_SQ
MR">O_/+,-^_\\]!'+_WTU%=O_?789Z_]]MQW[WUU(6CPP??DEV_^^8=EP(`%
MZ+?O_OOPRZ0^^_'7;__]^&,T?_[\]^____O[GP`'2,#R!;"`,.F<=NR"L9/=
M"#>@NQQ=*I<74&6+9`]T(,^@4[>HR<UOD$(2`D>HM`.2T"4=RQO.)/5!Y-QJ
M3??9(*LF-IP&B3!<[JK6"@]&'=2!2D?^8VF<R`:EN9)]K(;W$IP0->A!'U[L
M+G.*HA1/2!(34G$E*5P1WUBH);S-;6:_>9;=R%,CB#EK91&"5]80PQQ\O>J-
MG7(C''FHLZEQ,(<DPF$>R5,F9+&-2#R[HO[6)\B6V&J'R9J9PIK%-BXZY)"`
MA$BT)G5(]K2K;]-!DXS0]3-;^=&.#W//JG(8G5F-TI%BC-G<"ND1*[+2)$%"
M9+H41D<\UB>-#XFE#26)+5GJ45PRPXW8#*-)(G+15#@:EGPDLII3-LN(S\D5
M*C,UQC&^\B*NO.9(MEC$9`X3DCLK'>;`YJ9`0@V3'0*8#F4VS,(`:).YJN0+
MMQ0C<Q*-9O+^-"4YN4-+KC7,FMJD2#8#"I)++JR/NOJF&OMB3X2^[6BI*F/1
M<`FW@R:F-NA$54(7&LMIMBF2P=0:#A<)0F;5LE$-)2A#!JK21/4H:QAU5^#B
M:*>&[M)F$+VGJM22,X&M<S&.,]:XAA3-.3DQ=5/\W,@V!DT?GNYO$%SJ6JK6
MTHVPM*H:.:5,^?FSF>X3D.;4:CO%J-.$61!G/K4H5M>:/D*R]4U4]6H>\^G%
MG#6RJV?*(B_/V,M_TO%'8/3=.%\VV+<.Y*J&I<@RVY:F/8I4BZVBY0;#^-"[
MS3%L27RIARA62^*EE%Z?Q2IB$RO)QXV.IYC,F,<X)1W6!G%SR7S^G&HA6!<^
M5M:%-SQB28\76GGUUB(D`(%PA5N"@Z`@!,,5+@H64H(/X`,#^/B`"18R@@\D
M][H@&,$)%-)<["97!---2'>O^X'B)H0$'L@`!C@P@N66X![A5<@(.H`!#&P@
M!-M-R`FNF]^!B,"ZR?U`")8[D=$F9`0A.(""%QR"!B_X`.9%"`I$T($,X,,#
M)%C(<1/\X`9S>,$9/L@)'LQ@!X/W(>C%1P8P+)#@$I@@)NBPC!<<WX$@F,0'
M\/"#1?#B@MRXPPX^``EZ'+S?DI8_1O9583VR@08T@`%/G@"14_`!)SN9`0^(
ML$%*@($',``"$_`R!#)0XX)@@`%0MK+^`];\9`=$`!_]+4@'GFSE!JQYS5"&
MP`5";!`.T-G*:.8`0DR``0<T0`(3@,"A*Z#H$2A$!!9P``,B,`%)2X`#4Q;(
M""1M90K$%P43^#.=(5#FAQ@8(1:HLY/O+&DH,V`#"?%`J`\=`08XH`(B$*^A
MT[QJ-J/YR?0SR`B\7&=6.QD"%``!<R]@Z`A(X`$.H(`%'D#J/E_9SL7^L[()
M@H(*B-K.ODYSEA%2`5Z#V]<.N+1GC\S*$P0W`M@6-$%.(`%L0P`$)<AT"@X`
M`2AK8+LFP`>:(Y#K@YA@!*DV=`5(P'`2;&#7%(CS0-RM`39'8`0-]X"BO\SG
M>9.``ZS6``G^)"X0$TQ@`1`8<`I.H/$%V-G1".F`I!_P@>62H-P,J$"I4X""
MCQM:TA.(<`G0^X`&/`##6H[(J0U.@@_4V]`:&'IU4_UJ$5_@R1)H+PH^X&4'
MR-L@/1\!/K!]<8:+@`,2@'*P"])S#Q3=SO=H.`A"#64/G+?6!%^N"1[N\FH7
M9`-8WL`(#O!V"9!`!!DP]+9A/`*-6[D##&]\JHV>](&80`04P/:>S9Z!*X\/
M>$MFMP`U8&\M`Y[-%Y"OHAN`@8)0/0*5'\@!4.]Z.S/`[@@Y`00,/8&"^%G2
MK9=PO1L``9(/1`-0#OY`2C`!6\/<(!ZP\N<%0N\G5T#?*9`YGB7^D'3U:6"0
M:Z=(DPV-^X&<&=8&.3/QM?P!0S>@`PI!`;P;$(&"G*#<X3?(U==\`(*0P.+&
MEP(7`&5?)Q`BT&\14&J`!W\KMWL-0`&'Q0"+9Q"=MV8A(&>4IQ`@@&W?1Q#>
MEF[8)WHB>#CC9VC*5P(/4&F&E@$)@0*9YP!^-Q`D`&T-D'\#$0*T1Q"D)VGH
M)V*K)P$]-GL*UX*91W\!"&I.9G@%80)I]WP$40*K!X$%$7V2QH`(@0'@Q@#<
M1Q`;.($"Y586,7[O-W$H4`(-T($$466&UH,#,7D/T'%L-WP1\&(H<`(F\``5
ML!!C9X'S!F\.\(8^Z&05(''#]@"EQ@'^$9!?)N"`4M9B#^"%!%&"$SA=5Q=[
MLL=F^%`0>SAN(3B"GG@V.WAG_2>`$8"#*Y@0(:!Y!_&!#N"$!&&*#9!Z!%&!
M#&"%!K&(2=AC:L@`LFA<11B#;!=JA@8!&%!>,F@!L2>&MEAR#B@!`9@"#_=S
M6AAAL^>*!0:&%2&&N'<"$0!K'U!P`X&$?UAYNYB)N2>'X5@![',`D%@0%>@`
M%SAQ-`B,$^>'AZ8!^'6#%T!R=FAYC/AB)H!]H1B/V4=J)]`!S[AOF&AF=I:(
M//>)$/D2`#44&A`!6,A[*2`"#?`!FW:*"+&'8V@08EB`KYB#+39_$&")*;"(
M&#EQWN9D!`G^=B](CY$(9;MF=!7`7BTHC`X`CAX(;CY9$!7I`=*XA0H)A]=H
M@Q$AAB(':0R`AC[&9A0P92AH:$!XCL>&<0<P@'G8$._HDW,&?`DQ@+Y&?Q?@
M`2JYA/_H$*$(>2/``0\P;@PAA&?H?Q%@:.88D80E1$4E4DXD1:X%'9232]HB
MF*KU2'&E*<8$%!K`??;(`170>R+`9BR(:N#6CE3(>@AABFY67\\%;U_6COZX
M9L2(`1F0`73G=?$WDSM'?5B89KMF:Q0PBO;GAREY$/O7`.5G$!5)93]W:,4U
M>T@I$4N7$"7(9B['AFF(;39H`GYHB%AI;"ZGE!0(;A:@`1JP`<S^AF:>EA`F
M0`&_5I8/L&<,P9(-T(@-$8IWUG>M61!T.0'8N0$94&M?EI!Z&2S'HEFB)#=#
MM2_Y\BCVI$N,)4<UDS?KE&0IT9MJZ'X7.)D>>1`)!X\'H8:QN)EW]@`1``$+
M`&41P`%IN9*[MV810)]8I@'6R':_V)X"$0(9(`&MAFVV!HG.:6>WJ7_8MIM"
M.8>^:7O<-YG#J738*'[8A@$A\`'@J9P#0:$VR(UV)I<&47WT!P(AX`'XYQ#O
M"`$N^FL6X`&=B`(>8`&@N6I/!@$_.IKGV8G'!V[X"`+X\(<J>HEK]@`2T&]0
M=FD?>I_`DD2`$RC.A%.5%"(2PTQRHDK^``5./G-7/U&1R_6!-6B`E)D0%ZF;
M!_%[=7D0L&@!=9AP$5"F9NJ,*"")#.&"-/JF`H$";UD!Q,9[1%9]?WBB$1J3
M.4I@[8=M$K`!@(A-03H1VEAR#@"5!$&77:F6PQB`4"H!X2@!4KA2EYF1-%B9
M#F$"X5-IMB9IO3AH:YF>X$:;%7>G"GF*)U"$SHBG2:.GMZ5;#(6H3R0L>O5(
M&N-/G30MATHS0J&H&?ES,.>@#>"LT,>!!Q&IH@F+LCB#5OFFYGF54/H`)\IM
MK(D0)&`!UD@"%1>GE>>O8/=T-7H0]"H0L_IS#L"I5IJK$J&,-YBPN&B$!H&O
MP?JD<OAB@T?^99BJ$.\XBB!)DNZ)`64V8<S6;"%HGNC)$*&X>"=0<R9@`4'I
MG@M9KX8VE>)*6`R36>S$(V#E($[K6&/%-4]C3205KQ-)$QF+`0N@?/BJKVKI
M9#U+??,7KI9JDK2H?-::BP*1F1.0D*)*?*TI`EJX<SOHI/[%9FSKJ&)IG#J:
MI+_9L>"'$2+KE>`&J]"(;=.GLDX6N/[X``GYCO$(A:M6M`-Q#POPL@8Q>0[I
MG0ZHM-BZ9I!X9J(I$'29EXSJJTL[+UMT4_LD*?WI2[[448^5M2LT-'\T,/WD
M$Q<`G2E0`DKHMYH9:U:&HWYF9Z=+E[TX@S>J$+JGJM3W=,4K8;/^]KDG"W25
M=P]/)KIF!F6WVH;'EI9=1F0A4'1KYK%>";)+^;P-40+SE[(K"9J<:UPK.V_@
MB;T'$;-I:I4!&'VQ2'*DQXL+P;,/\;.^I[P*<0#8EI<.NF;VV;J&@BD*%!<+
M)%7-%#I1M<%_B42]<3KM>I@@#$V+F1,3IFA?IV64.@$J.L`0`(X@0&PT2Q"4
M*@'QA7R&1G.M*82M.A`;&&_Y=A##%J>*Z[>3-H'"BV4)>W_<&5]^AF5%O'QW
MV;@KBK[JNU+L^Q`HD'#Y^A"$!V4]>`)4Q\(+S&97R7,'<+W/>`+"V`!?-Z.&
MAHQ3!L`,,`%.2`)XY[&<2:8-\:V)NWS^G:?`QHEMUV=^MA:+^1;!$KS(4_(!
M\+:A6E@!S]<!]89F#(!R.I<0':"A#I`!]/5D$8"C-`R::(;)Q84"5U?*99L"
M(."BD+P`#C`!!0=RI7RQ&EMIKYQN5)R1QR9I%+`!]`5TF#MQ&?``"]"-'8!S
M%)"P)6`!8;8`+C<!%&"+,4RXN$J=#+$!%$"B:"8!%8"D0MQ\F^L!:.=R%]":
M)E`!%-!J4%8![IQVD"RY!]',W'R>#,AOKN8`HNP!>>9D%M`!'E!H#+#,"M$!
MTFK)#Y!L":$!%$"GW>S.ZPS)$H@0&T!WEAP!^[B2.+<`#V`!,\S(]A-ZAR'2
M)@$"]76:&7#^`>3YMA=@FBA=7RIJ`LD,`1`0`18`7PKA`2V-TNJ%`1'V`<Y\
M`;2ICRY]FAAP`<^WE1.PI>:[TR]]`9`X`A-P#R=0`C-=TQ=0<PWA<(F&I1@`
M`MC'94Y]U%M:$"$``0D+$<7Y=])F`2I]`1:@SN!L7!]P`1%`;1*0`<-<<N[L
MUBH=U^ZLCG^=`9G6S!7PUG`]S<N'#Q,P`1E0>7/W`2<P`AJ0:!@*U9W(`=*&
MV!9``;M\?)O]UH`MV&^=L!I`VBI]V/F%`AU``?`Y`GL-TO&#H$=!VT11AV@*
M$;D=?QE!9+@]$;^]$2+`K0NQUB!1AR>PVR:!`LI]`LDMV]"]$;;^7133_5;&
M'=W8;3@D[4[5;=U9G-W@'=[>C<WB7=[F?4W7?=[JO=[\D][L_=[.L[7P'8'D
M/=_V?4'4)%6U12>B`D6):2,9]$#YK4S^?40=7."*.46X9:ZS)4,I$N`+#D#?
M?=\4KI_G*D*,-*`>A;L!>N'P%"X1A>&<]"`&55)A533^&2M;%3_N7>'JS3B@
MY#`AWEA^BE.<)%;KZBK%-%;>U%@G/E&YM"X27M^MZT$N?KO38KM\I>!^5;7O
M8IB3TUI*@J[S9#1*3E;QNC97CC\M/H*BPT#B5#FHY1QD7N:"*3H>'.42PI^K
MI1LM%.%3`E+MD>'R>N&7@KLZTRU/6U;^!N-)Z:KA-O3C)A7D>CY`72YZ;23D
M.U3EM-LU?!*[724T<EXW?75)%+7EV"&@?Y3A/;Z[>XZ8A;XOFGY7,?7I5T,W
M2]:[*#[E='4_A\YN$I5:*B2O?E+K,W1;#`(K8%1*E?Y7P+3JUG$Y!I[HT@+E
MW20M_XV8D/,QPC[L&(SLBUG!*UY$2(1,P&X_K^Z)]Z)*!S7IIDX@LSM97X0W
M9@59ZZ)#@77DZIWM7H[E8E/N"Q7O3SOI*55-Y9%6;L,WEWX]VZTA_8Y7`&_H
M$R[;&0ROQ1XWFA)46MXEHF+M[S[B0_3G3[3OBSX]W9U)X,WN(KCM#V56N4%3
M(.](Z4Y-67[^+>T"X\1^63]%/1</5.`=/I^=W1Q?X^:.-2DN1^GDY')5*FI!
M\6I"\2.O//^.(4.O[FLUM4#^6/]I2S$>\#;#[6ZT\FCEZQ5O]%8?W4XK63,%
M,'W5[2F_ZEP?2/H^Z^A.]5=_]EA/Z62#\&^C+U>K]5HS27>C(O!^3%3?\FB?
M]]=T')R3\`F/.INSW\MA+##"0'##]Q$$.DV[P;+AYKD%YWH?^9(_^91?^99_
M^9B?^9J_^9S?^9[_^:`?^J(_^J1?^J9_^JB?^JJ_^JS?^J[_^K`?^Q<BW[)?
M^[:?,>DJ0;!U5!5#.32$X+[Q5-3>EP7^EZ'R,`HT01A\P8/_0[?^__R\\_59
MNTN4A%G\N3-><NLQM$I4JRNSN^#T;OW0_SR&3TH2Q!NRU4T73#JH151JCN1G
M!3*C\^9%[^\JG_TE3T_W+DV<CO\V#D\``2#%P($""19,8?#@0H8*$RX4Z)!@
M1(0'%3JDV+`B0XX=/7X$&5+D2)(E39Y$F5+E2I8M7;Z$&5/F3)H<)3ZT>'-C
M0H,`+EZ$J-.G18@>;^K4N',HT9U)F2IUBA/H1*@X:U[%"C(CQJ(3E]JTZ5-L
M3J%?B?;4:I6J5Z$?)6[M2M8D5[D:T19]:Y9M5KY]_?X%'%CP8,*%#<==B[!M
MU[>)"Y9]VC2RY*@],U8-BU@MTK5T/4_^/APZ[4.ZCB]'-7T6[.+3JRNK33S6
ML538C2D;G=RZHN[6NDF+!AY<^'#BQ8T?'UF:ZE&WN%4_;\I9>?/9RI&>9CX[
M[N?.H)$?_KF=<<?%F#=+#M\\^VZPT;?;CEUR:N32>G_39\KY^W[^_?W_!Q"\
MW*H;#;7>SO/./)+@0XT][6BC#D'N;@N0+]E@XRDORX+2\#'+Q,)HJ:\NU`\]
M$4]LZ,(,]U)JQ*%4=`O$%&5D$</:0`QQPPIWY+%''W_L$4?X&"2OO>X<=(\\
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M7:^Q8-897**S]Q=AEZO#O/:$K]?Y^^C"GU+H*`<>6K:BJ8<_?OGGI[]^^^_'
M?WZ?\^>_?___WU7M`#A``A;0@#L2X`'^%;A`!C80,/MS8`0E.$$*5M""%\1@
M!C6X00YVT(,?!&$(13A"$I;0A"=$80I5N$(6MM"%+X1A#&4X0QK6T(8WQ&$.
M=;A#'O;0AS\$8A"%.$0B%M&(1T0BY\BWLTBY[T7Z.E'W$*:D'-&K7U6$X-!D
MYK+K0#")7P2CQT*'F:DH3V60`<W'KC8GM\FMC5([V^/".$<'FI%RK;(C&J/6
M.L?=1ENOVU9FT-8O#A42>]J3G.H0E[D::;%&<'Q?T.YE/IX)[9&)I&,FVX2=
MU-@1>'XS7:IXARHW`LLI!TJ@[JQ6JM$A+UFG9-BB?!=+9W4M;XLZ7Q_9I,E,
M<F64;2L4\5#^2<I?BK)!90+*[P2'NO.([DP+,I@R&42LYW!J?+)#ENODR$MN
MXI*:X9H<](@7+):Q$7;&1%+DXC@W1"YOF^,B4N.>%\\T:25QC'MF-<_936YZ
MDHROH1":!!HA?S+)G)`36RHWQDQ??BUU!<HF;:894;18DT#&4E.BAN1%?B)1
M>+Y;(R2=4T9BGNJ@)5W30&MYM%;:<GBDA"4@R>E*Z,7)HMZDZ'MBVE%^5E1@
MINJ=\<0#IY2:TJ`1,E(R8<I2]-7%BH:KV3V/PC7O47%&2]VB)'-$G^R=D:,\
M/2)<U.8ZNY`UJ37]:>R8ATZ`VDVA8(7)6^$*5K$6R:=Q\XUIKIG^3Z->KHT,
M=9M<\??5/@GV6"\A[%Q[N#9TE2L_^9JB]^ZUIYD]J;(](TN=9(9!PPJH)HF=
MBV)%.]I:8:FS8B)M:E4+'-#>ZK1_:>UJ93M;VM;6MK?%;6YUNUO>]M:WOP5N
M<(4[7.)N\)`_L^PED>M$9B*7LIB\IW(CN;VI3E6ZL2UN=F>XNP%9%SVIZ]LQ
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M.FF`+?15APS>IB8X<XL^ZH_W9FI:$SJ?F?Y9,?DJ5%X7E=,N_NZOV5IK8D^O
MT,*+<(H='6Q)GYC!GGY:H1):;&I+K\\DPO%6A8QC'Y?/BUITXJK];+WVS2S0
KU49WNM6];A`@BIG=[QXNJ>$];]+*F][WYJF[\;UO?O?;W_\&>,"O'!``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
